Top Markets
#1 NEW X CEO IS BACK NEW X CEO IS BACK +80,967.86%
#2 Beta Finance Beta Finance +9,043.03%
#3 Orochi Network Orochi Network +105.17%
#4 Tribe Tribe +69.90%
#5 Chainbase Chainbase +45.67%
#6 Freysa AI Freysa AI +40.65%
#7 BabyBoomToken BabyBoomToken +36.91%
#8 Block Street Block Street +36.41%
#9 Chrema Coin Chrema Coin +27.48%
#10 パンチ (Punch) パンチ (Punch) +20.85%
Coin of the day
NEW X CEO IS BACK NEW X CEO IS BACK
Settings
Language
ENGLISH
Currency
USD
Theme
Nuformix plc Nuformix plc

Nuformix plc

NFX
Rank in Stocks #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Share Price
$0.00244926
Market Cap
$51.67K
Change (1 day)
5.88%
Change (1 year)
110.15%
Country
GB
Trade Nuformix plc (NFX)

Category

Healthcare
P/S ratio for Nuformix plc (NFX)
P/S ratio as of March 2026 TTM: 0.00
According to Nuformix plc latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.00. At the end of 2024 the company had a P/S ratio of 0.00.
P/S ratio history for Nuformix plc from 2014 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
2026 (TTM) 0.00 0.00%
2025 0.00 0.00%
2024 0.00 0.00%
2023 0.00 -100.00%
2022 116.70 74.68%
2021 66.81 87.30%
2020 35.67 81.62%
2019 19.64 -95.96%
2018 485.61 0.00%
2017 0.00 -100.00%
2016 2.23 0.00%
2014 0.00 0.00%
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
3.55 -
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.90 -
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
5.40 -
US
UCB SA UCB SA
UCB SA
UCB.BR
6.14 -
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.04 -
AU